Latest Nasdaq Biotechnology Ishares (IBB) Headline
Post# of 26
OxySure's Improving Financials & Operational Milestones Paint a Bullish Picture
ACCESSWIRE - Mon Mar 10, 8:01AM CDT
Whitefish, MT / March 10, 2014 / The healthcare industry has been attracting record amounts of capital in 2014, driven by biotechnology and pharmaceutical companies bringing new products to market. In fact, more than half of all money flowing into U.S. sector-focused ETFs, or $4.06 billion through February 28th, was placed in healthcare ETFs, according to data compiled by Bloomberg.
Technical Analysis 101 - Trend, Trace, and Trigger - Analyst Blog
David Bartosiak - Zacks Investment Research - Thu Mar 06, 3:45PM CST
Three technical indicators to help determine the direction a stock is moving, potential areas of support and resistance, and when to buy.
SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 2.84% Loss
Comtex SmarTrend(R) - Fri Feb 28, 4:11PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $260.97 to a high of $273.02. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $269.14 on volume of 3.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 2.84%
Comtex SmarTrend(R) - Fri Feb 28, 4:07PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $260.97 to a high of $273.02. Yesterday, the shares fell 2.8%, which took the trading range below the 3-day low of $269.14 on volume of 3.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
iShares Nasdaq Biotechnology Index Fund (IBB) : Short Sell @ $268.69
Trading Central - Fri Feb 28, 12:59PM CST
From a technical view, the ETF is posting a tentative reversal candlestick pattern on a weekly chart while biotechnology sector is in a parabolic rise. Regarding technical indicators, the weekly RSI is posting a tentative bearish divergence in its...
'Fast Money' Recap: A Stunning Move
at The Street - Tue Feb 25, 4:00AM CST
The trading panel discussed the S&P's move higher and how long that can last.
SmarTrend Watching for Potential Pullback in Shares of iShares Nasdaq Biotechnology Index After 1.25% Gain
Comtex SmarTrend(R) - Mon Feb 24, 4:39PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.01 to a high of $273.88. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $271.05 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
iShares Nasdaq Biotechnology Index Rises 1.25% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Feb 24, 4:39PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $270.01 to a high of $273.88. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $271.05 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon Feb 24, 2:33AM CST
Bull of the Day: Alexion Pharma (ALXN) - Bull of the Day
iShares Nasdaq Biotechnology Index Rises 2.61% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Tue Feb 18, 4:54PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $259.81 to a high of $264.58. Yesterday, the shares gained 2.6%, which took the trading range above the 3-day high of $260.94 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Top Ranked Healthcare ETF in Focus: XPH - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:01AM CST
This top ranked fund could be a great way to target the strength in the health care market.
Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 1.58% Yesterday
Comtex SmarTrend(R) - Tue Feb 11, 5:31PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $250.48 to a high of $255.29. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $250.72 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
The Guide to Surging Biotech ETFs - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 11:00AM CST
Investors should not ignore this high growth sector that continues to deliver strong performance
Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 4.03% Yesterday
Comtex SmarTrend(R) - Fri Feb 07, 4:47PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $237.66 to a high of $246.36. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $242.50 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
iShares Nasdaq Biotechnology Index Rises 4.03% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Feb 07, 4:46PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $237.66 to a high of $246.36. Yesterday, the shares gained 4.0%, which took the trading range above the 3-day high of $242.50 on volume of 1.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.